Effect of bariatric surgery on the adipose hormone adiponectin in obese women.

Not Applicable

Recruiting

• Conditions: Obesity; Diet and Nutrition - Obesity

• Registration Number: ACTRN12611000525987
• Lead Sponsor: The Univeristy of Auckland

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-05-23
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 45

Inclusion Criteria

Phase 1 A Lean: BMI 18.5-25 kg/m2, weight stable and healthy.
Accepted into the Auckland District Health Board Auckland City Hospital General Laparoscopic Upper GI Surgery Clinic. Accepts reversion to open surgery if necessary.
Signed informed consent given.

Phase 1 B Obese: BMI >40 or >35 kg/m2 with co-morbidities and weight stable.
Accepted into the Auckland District Health Board Auckland City Hospital General Laparoscopic Upper GI Surgery Clinic. Accepts reversion to open surgery if necessary.
Signed informed consent given.

Phase 2: Body Mass Index (BMI) >40 kg/m2 or >35 kg/m2 plus co-morbidities of diabetes, polycystic ovary syndrome, fatty liver disease and severe dyslipidaemia.
Accepted for Bariatric Surgery at Auckland City Hospital
Signed informed consent given

Exclusion Criteria

History of inflammatory or malignant disease.
Previous obesity surgery – bariatric, liposuction, lipectomy or liposculpture
Pregnant or breastfeeding
Participation in another clinical trial
No weight loss medication of weight programme attendance.
No extreme food restriction and/or excessive physical activity and alters body composition in a short space of time.

Study & Design

• Study Type: Observational
• Study Design: Not specified